Chaitanya Divgi
Senior Expert - Strategic Therapeutic Innovation Novartis
Seminars
Tuesday 1st December 2026
The Great Isotope Debate: Which Therapeutic Radionuclide Will Define the Next 5 Years of TRP Development? Seven Isotope Specialists, Seven Perspectives.
9:00 am
Experience a fast-paced debate, where isotope specialists will each present the strongest case for their radionuclide before joining a moderated discussion comparing clinical evidence, manufacturing readiness, supply considerations and commercial potential. Hear contrasting perspectives, challenge conventional thinking and take part in the discussion as the audience helps determine which isotope will define the next five years of TRP development.
- Comparing the scientific, clinical, manufacturing and commercial advantages of emerging isotopes including Actinium-225, Lead-212, Copper-67, Terbium, Astatine-211 and Lutetium-177
- Evaluating which radionuclides are best positioned to win across therapeutic efficacy, supply scalability, dosimetry flexibility, theranostic integration and global clinical applicability
- Challenging each isotope expert to defend why their radionuclide will become the hottest, most commercially impactful and most clinically transformative isotope over the next five years
Tuesday 1st December 2026
Alpha vs Beta: Determining When, Where & Why Different Therapeutic Isotopes Deliver the Greatest Clinical Advantage
11:30 am
- Evaluating how alpha- and beta-emitting isotopes differ in tissue penetration, potency, bystander effect and suitability across distinct tumour and disease settings
- Understanding why isotope selection should be driven by tumour biology, disease burden, delivery vehicle and therapeutic intent rather than momentum toward a single modality class
- Defining where alpha emitters may offer transformative efficacy versus where beta emitters may provide superior tolerability, scalability or broader clinical applicability
